Cybin (TSE:CYBN) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cybin Inc. is set to present promising 12-month data from its Phase 2 study of CYB003, aimed at treating Major Depressive Disorder, in an upcoming webcast. The company is also moving forward with its Phase 3 PARADIGM program, highlighting its commitment to revolutionizing mental healthcare. Investors and stakeholders are invited to join the discussion for insights into these innovative treatment developments.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue